The management of gastrointestinal disease in Hermansky-Pudlak syndrome

J Clin Gastroenterol. 2011 Sep;45(8):700-2. doi: 10.1097/MCG.0b013e3181fd2742.

Abstract

Hermansky-Pudlak syndrome (HPS) was first described in 1959 by Hermansky and Pudlak. Clinically, HPS is characterized by oculocutaneous albinism, platelet storage pool deficiency, and ceroid tissue accumulation. It is a rare disorder that has been described globally but has the highest frequency in a cluster population in Puerto Rico. HPS patients also have major organ involvement that typically includes pulmonary fibrosis and granulomatous colitis. Rarely have cardiomyopathy and renal dysfunction been described. We report a case of the oldest historical patient with HPS type 6 and the associated gastrointestinal management.

Publication types

  • Case Reports

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Blood Transfusion
  • Enterocolitis / etiology
  • Enterocolitis / therapy
  • Gastrointestinal Agents / therapeutic use
  • Gastrointestinal Diseases / diagnosis
  • Gastrointestinal Diseases / etiology
  • Gastrointestinal Diseases / therapy*
  • Gastrointestinal Hemorrhage / etiology
  • Gastrointestinal Hemorrhage / therapy
  • Hermanski-Pudlak Syndrome / complications*
  • Humans
  • Male
  • Middle Aged
  • Probiotics / therapeutic use
  • Steroids / therapeutic use
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Anti-Inflammatory Agents, Non-Steroidal
  • Gastrointestinal Agents
  • Steroids